Why the study?
Does intracoronary adenosine adjunct to primary PTCA improve flow, ventricular function, and clinical course in patients with acute myocardial infarction?
Does intracoronary adenosine adjunct to primary PTCA improve flow, ventricular function, and clinical course in patients with acute myocardial infarction?
Intracoronary adenosine administration as an adjunct to primary PTCA in AMI appears to improve coronary flow, prevent no-reflow, and improve ventricular function.
Supports adjunctive intracoronary adenosine in primary PTCA for AMI; confirms microvascular and functional benefits in RCT.
Intracoronary adenosine administration is feasible and well tolerated in AMI. Adenosine adjunct to primary PTCA ameliorates flow, prevents the no-reflow phenomenon, improves ventricular function, and is associated with a more favorable clinical course.
No takes yet. Share an insight, caveat, or question.
Marzilli et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: